Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell Responses
Emily Corse(Howard Hughes Medical Institute), James P. Allison(The University of Texas MD Anderson Cancer Center)
Cited by 203
Related Papers
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
|Proceedings of the National Academy of Sciences|2019|357
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
|The Journal of Experimental Medicine|2010|271
Attenuated T Cell Responses to a High-Potency Ligand In Vivo
|PLoS Biology|2010|112
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy
|Proceedings of the National Academy of Sciences|2024|19